

Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.



COMPASS® Hematopathology Services

Alternative Name

COMPASS® Bone Marrow Evaluation, COMPASS® Peripheral Blood Evaluation

Methodology

Cytogenetics

FISH

Flow Cytometry

Immunohistochemistry (IHC)

Molecular

Test Description

COMPASS[®] is a comprehensive diagnostic solution, guided by a board-certified hematopathologist that provides an accurate, actionable, and definitive diagnosis for complex hematologic malignancies.

Includes COMPASS[®] consultation report, clinical pathology evaluation, bone marrow morphology, flow cytometry, cytogenetics and/or fluorescent in situ hybridization (FISH), and molecular tests as medically necessary.

Note: If an NGS profile is medically necessary and FLT3 by PCR is added on to provide faster results for the purpose of prompt therapy selection in cases of new or suspected AML diagnosis, the additional FLT3 test will be a client-bill only test. Please contact Client Services for more info.

Clinical Significance

Hematologic malignancies consist of more than 100 different subtypes of leukemias and lymphomas. Frequently, blood cancers require a comprehensive laboratory work-up with multiple test modalities in order to generate a differential diagnosis and render a definitive diagnosis.

COMPASS is a selected and personalized lab work-up to provide diagnostic clarity and often prognostic or predictive information to help inform effective patient care management.

Specimen Requirements

- Peripheral Blood Kit:
 - (1) 6 mL in EDTA tube AND
 - (2) 6 mL sodium heparin tubes AND
 - (2) bedside smears
- Bone Marrow Kit:
 - (3) 4 mL sodium heparin tubes AND
 - (1) 6 mL Peripheral Blood and (1) 4 mL Bone Marrow Aspirate (or Core Biopsy and/or Aspirate Clot of >1.5 cm in 10% NBF) in EDTA tubes AND

- (2) Peripheral Blood bedside smears AND
- (6) Bone Marrow smears AND
- \circ (2) Bone Marrow core touch prep slides
- Lymph Node: Not Available
- NY Clients: Please provide Date and Time of Collection.

Storage & Transportation

Specimens should be received at NeoGenomics within 72 hours from collection to assure sample integrity and acceptable cell viability. Note: New York State samples must be received within 48 hours from collection per NYS requirements. Ship same day as drawn whenever possible. Refrigerate specimen. Do not freeze. Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*

Refer to individual tests for CPT Code(s)

New York Approved Yes

162

Level of Service

Global

Turnaround Time

8-10 Days (14 Days if NGS testing is included)

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way Fort Myers, FL 33912 Phone: 239.768.0600/ Fax: 239.690.4237 neogenomics.com © 2024 NeoGenomics Laboratories, Inc. All Rights Reserved. All other trademarks are the property of their respective owners Rev. 051624